Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | EML4 | Q9HC35 | 3/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.37 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.37 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144651 | 1.00 | SIRT2 (0.46) | SIRT2SIRT1SIRT3MAP3K5KIT | |
| SCHEMBL2144030 | 0.90 | ALK (0.43) | MAP3K5KITFLT3MAPK8MAPK9 | |
| SCHEMBL2144020 | 0.90 | ALK (0.43) | MAP3K5KITFLT3MAPK8MAPK9 | |
| SCHEMBL2144894 | 0.89 | KIT (0.51) | MAP3K5KITFLT3MAPK8MAPK9 | |
| SCHEMBL2144890 | 0.89 | KIT (0.51) | MAP3K5KITFLT3MAPK8MAPK9 | |
| SCHEMBL2144529 | 0.85 | IRAK4 (0.45) | MAP3K5FLT3MAPK8MAPK9JAK2 | |
| SCHEMBL2144537 | 0.85 | IRAK4 (0.45) | MAP3K5FLT3MAPK8MAPK9JAK2 | |
| SCHEMBL2144725 | 0.84 | KIT (0.55) | MAP3K5KITFLT3MAPK8MAPK9 | |
| SCHEMBL2144723 | 0.84 | KIT (0.55) | MAP3K5KITFLT3MAPK8MAPK9 | |
| SCHEMBL3303940 | 0.83 | RHOA (0.47) | MAP3K5FLT3MAPK8MAPK9JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | claimed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | claimed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | claimed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | claimed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | claimed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | SIRT2 2336/4885SIRT1 2678/4885SIRT3 2333/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | SIRT2 2336/4885SIRT1 2678/4885SIRT3 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.